TCF1 links GIPR signaling to the control of beta cell function and survival-Reference-Cited by-同舟云学术

TCF1 links GIPR signaling to the control of beta cell function and survival

Published:2015-12-07 Issue:1 Volume:22 Page:84-90
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Campbell Jonathan E,Ussher John R,Mulvihill Erin E,Kolic Jelena,Baggio Laurie L,Cao Xiemen,Liu Yu,Lamont Benjamin J,Morii Tsukasa,Streutker Catherine J,Tamarina Natalia,Philipson Louis H,Wrana Jeffrey L,MacDonald Patrick E,Drucker Daniel J

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.3997.pdf

Reference45 articles.

1. Campbell, J.E. & Drucker, D.J. Pharmacology physiology and mechanisms of incretin hormone action. Cell Metab. 17, 819–837 (2013).

2. Saxena, R. et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat. Genet. 42, 142–148 (2010).

3. Speliotes, E.K. et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat. Genet. 42, 937–948 (2010).

4. Miyawaki, K. et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8, 738–742 (2002).

5. Mulvihill, E.E. & Drucker, D.J. Pharmacology, physiology and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 35, 992–1019 (2014).

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain;2024-08-16

2. Cross-talk between oxidative stress and lipid metabolism regulators reveals molecular clusters and immunological characterization in polycystic ovarian syndrome;Lipids in Health and Disease;2024-08-15

3. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists;Frontiers in Endocrinology;2024-07-24

4. Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity;Expert Opinion on Investigational Drugs;2024-07-17

5. Evaluating glucose-dependent insulinotropic polypeptide and glucagon as key regulators of insulin secretion in the pancreatic islet;American Journal of Physiology-Endocrinology and Metabolism;2024-07-01